Canlyniadau Chwilio - I−Ru Chen

  • Dangos 1 - 3 canlyniadau o 3
Mireinio'r Canlyniadau
  1. 1
    Association of Walking with Survival and RRT Among Patients with CKD Stages 3–5

    Association of Walking with Survival and RRT Among Patients with CKD Stages 3–5 gan I−Ru Chen, Su-Ming Wang, Chih‐Chia Liang, Huey‐Liang Kuo, Chiz‐Tzung Chang, Jiung-Hsiun Liu, Hsin‐Hung Lin, I‐Kuan Wang, Yafei Yang, Che‐Yi Chou, Chiu‐Ching Huang

    Cyhoeddwyd 2014
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  2. 2
    Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults

    Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults gan Thomas Barbour, Marie Scully, Gema Ariceta, Spero Cataland, Katherine Garlo, Nils Heyne, Yosu Luque, Jan Menne, Yoshitaka Miyakawa, Sung‐Soo Yoon, David Kavanagh, Sunil Babu, Nilüfer Broeders, Nicole Lietar, Fiona G. Brown, Philip Campbell, Josep M. Campistol, Paramit Chowdhury, Theo Kasimatis, Lino Cirami, Leonardo Caroti, Guilia Antognoli, Yahsou Delmas, Vladimir Dobronravov, Anja Gaeckler, Cyril Garrouste, Gregory Greenwood, Siân Griffin, Chiu‐Ching Huang, I−Ru Chen, Susan S. Huang, Jin Seok Kim, Gaetano La Manna, Moglie Le Quintrec, Guillaume Jeantet, Iino Fumie, Éric Rondeau, Hermann Haller, J Morelle, Éric Goffin, Anja Mühlfeld, Shashi Nagaraj, Gowthami M. Arepally, Doyeun Oh, Masayoshi Okumi, Manuel Praga Terente, François Provôt, Ulf Schönermarck, Michael Fischereder, Natàlia Ramos Terrada, Barbara Seitz‐Polski, Guillaume Favrè, Sonia Boyer‐Suavet, Maria Vinogradova, Tatiana Kirsanova, Edwin Wong

    Cyhoeddwyd 2021
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  3. 3
    The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment

    The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment gan Éric Rondeau, Marie Scully, Gema Ariceta, Thomas Barbour, Spero Cataland, Nils Heyne, Yoshitaka Miyakawa, Stephan Ortiz, Eugene Swenson, Marc Vallée, Sung‐Soo Yoon, David Kavanagh, Hermann Haller, Sunil Babu, Nilüfer Broeders, Nicole Lietar, Fiona G. Brown, Philip Campbell, Paramit Chowdhury, Theo Kasimatis, Lino Cirami, Leonardo Caroti, Guilia Antognoli, Yahsou Delmas, Vladimir Dobronravov, Anja Gaeckler, Cyril Garrouste, Gregory Greenwood, Siân Griffin, Chiu‐Ching Huang, I−Ru Chen, Susan S. Huang, Jin Seok Kim, Gaetano La Manna, Giorgia Comai, Maria Cappuccilli, Moglie Le Quintrec, Guillaume Jeantet, Iino Fumie, Yosu Luque, Jan Menne, J Morelle, Éric Goffin, Anja Mühlfeld, Shashi Nagaraj, Gowthami M. Arepally, Doyeun Oh, Masayoshi Okumi, Manuel Praga Terente, Elena Gutiérrez, Paola Rodrı́guez, François Provôt, Ulf Schönermarck, Michael Fischereder, Natàlia Ramos Terrada, Barbara Seitz‐Polski, Guillaume Favrè, Sonia Boyer‐Suavet, Maria Vinogradova, Tatiana Kirsanova, Edwin Wong

    Cyhoeddwyd 2020
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:

Offerynnau Chwilio: